CeriBell (NASDAQ:CBLL) CEO Sells $108,540.00 in Stock

CeriBell, Inc. (NASDAQ:CBLL) CEO Xingjuan Chao sold 6,030 shares of the company’s stock in a transaction dated Thursday, May 21st. The stock was sold at an average price of $18.00, for a total transaction of $108,540.00. Following the completion of the sale, the chief executive officer directly owned 830,317 shares in the company, valued at $14,945,706. This represents a 0.72% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Xingjuan Chao also recently made the following trade(s):

• On Tuesday, May 5th, Xingjuan Chao sold 39,000 shares of CeriBell stock. The stock was sold at an average price of $20.10, for a total transaction of $783,900.00.
• On Monday, April 6th, Xingjuan Chao sold 39,000 shares of CeriBell stock. The shares were sold at an average price of $18.40, for a total transaction of $717,600.00.
• On Tuesday, March 3rd, Xingjuan Chao sold 39,000 shares of CeriBell stock. The stock was sold at an average price of $17.45, for a total transaction of $680,550.00.

CeriBell Price Performance

Shares of NASDAQ:CBLL opened at $18.67 on Friday. The firm’s 50 day moving average price is $19.07 and its 200-day moving average price is $19.34. CeriBell, Inc. has a twelve month low of $10.85 and a twelve month high of $24.33. The company has a quick ratio of 10.01, a current ratio of 10.44 and a debt-to-equity ratio of 0.14. The stock has a market capitalization of $708.34 million, a PE ratio of -11.45 and a beta of 0.99.

CeriBell (NASDAQ:CBLL) last issued its quarterly earnings data on Monday, May 11th. The company reported ($0.52) earnings per share for the quarter, missing the consensus estimate of ($0.39) by ($0.13). CeriBell had a negative return on equity of 38.19% and a negative net margin of 63.51%.The business had revenue of $26.49 million during the quarter, compared to the consensus estimate of $26.09 million. Equities research analysts expect that CeriBell, Inc. will post -1.69 EPS for the current year.

Institutional Investors Weigh In On CeriBell

Large investors have recently modified their holdings of the business. JPMorgan Chase & Co. boosted its position in CeriBell by 6,424.8% in the second quarter. JPMorgan Chase & Co. now owns 380,003 shares of the company’s stock valued at $7,117,000 after buying an additional 374,179 shares during the last quarter. Rhumbline Advisers raised its stake in shares of CeriBell by 109.9% during the 2nd quarter. Rhumbline Advisers now owns 32,806 shares of the company’s stock worth $614,000 after buying an additional 17,177 shares during the period. New York State Common Retirement Fund raised its stake in shares of CeriBell by 148.6% during the 2nd quarter. New York State Common Retirement Fund now owns 8,700 shares of the company’s stock worth $163,000 after buying an additional 5,200 shares during the period. Quantbot Technologies LP increased its position in shares of CeriBell by 70.3% during the second quarter. Quantbot Technologies LP now owns 15,504 shares of the company’s stock worth $290,000 after purchasing an additional 6,401 shares in the last quarter. Finally, Invesco Ltd. purchased a new position in shares of CeriBell during the 2nd quarter worth $197,000.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on the company. Weiss Ratings upgraded CeriBell from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday. Canaccord Genuity Group lowered their target price on shares of CeriBell from $28.00 to $25.00 and set a “buy” rating for the company in a research note on Tuesday, May 12th. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $22.20.

CeriBell Company Profile

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.